Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Decision date
29/07/2026
Enrollment target
27
Sites
Germany
Condition studied
This clinical trial is performed in healthy participants; the planned indication: Treatment of Hereditary hemorrhagic telangiectasia (HHT)
Eligibility
Age group
18-64 years
Sex
Female, Male
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.